| Dr Philip L Schneider, MD | |
|
8401 Connecticut Ave, Suite 800, Chevy Chase, MD 20815-5803 | |
| (301) 949-8100 | |
| (301) 962-7450 |
| Full Name | Dr Philip L Schneider |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 41 Years |
| Location | 8401 Connecticut Ave, Chevy Chase, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265493308 | NPI | - | NPPES |
| 484431900 | Medicaid | MD | |
| 545271600 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | D0038014 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holy Cross Home Care And Hospice | Silver spring, MD | Home health agency |
| Holy Cross Hospital | Silver spring, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centers For Advanced Orthopaedics Llc | 8123260981 | 476 |
News Archive
The most common hormone disorder affecting women of reproductive age-;polycystic ovary syndrome (PCOS)-;cost an estimated $8 billion to diagnose and treat nationwide in 2020, according to a new economic analysis published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.
The rising popularity of shark cartilage extract as an anti-cancer treatment is a triumph of marketing and pseudoscience over reason, with a tragic fallout for both sharks and humans, according to a Johns Hopkins biologist writing in the Dec. 1 issue of Cancer Research.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.
› Verified 8 days ago
| Entity Name | Centers For Advanced Orthopaedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487093167 PECOS PAC ID: 8123260981 Enrollment ID: O20131024001780 |
News Archive
The most common hormone disorder affecting women of reproductive age-;polycystic ovary syndrome (PCOS)-;cost an estimated $8 billion to diagnose and treat nationwide in 2020, according to a new economic analysis published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.
The rising popularity of shark cartilage extract as an anti-cancer treatment is a triumph of marketing and pseudoscience over reason, with a tragic fallout for both sharks and humans, according to a Johns Hopkins biologist writing in the Dec. 1 issue of Cancer Research.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip L Schneider, MD 8401 Connecticut Ave, Suite 800, Chevy Chase, MD 20815-5803 Ph: (301) 949-8100 | Dr Philip L Schneider, MD 8401 Connecticut Ave, Suite 800, Chevy Chase, MD 20815-5803 Ph: (301) 949-8100 |
News Archive
The most common hormone disorder affecting women of reproductive age-;polycystic ovary syndrome (PCOS)-;cost an estimated $8 billion to diagnose and treat nationwide in 2020, according to a new economic analysis published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.
The rising popularity of shark cartilage extract as an anti-cancer treatment is a triumph of marketing and pseudoscience over reason, with a tragic fallout for both sharks and humans, according to a Johns Hopkins biologist writing in the Dec. 1 issue of Cancer Research.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.
› Verified 8 days ago
Dr. Randall Jeffrey Lewis, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5454 Wisconsin Ave, Suite 1000, Chevy Chase, MD 20815 Phone: 301-657-1996 Fax: 301-951-6160 | |
Dr. Antoni Bernard Goral, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8401 Connecticut Ave, Suite 800, Chevy Chase, MD 20815 Phone: 301-949-8100 Fax: 301-962-7450 | |
Harrison Solomon, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8401 Connecticut Ave, Suite 800, Chevy Chase, MD 20815 Phone: 301-949-8100 Fax: 301-962-7450 | |
Steven Howard Bernstein Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave, Suite 1660, Chevy Chase, MD 20815 Phone: 301-657-9876 Fax: 301-657-8240 | |
Dr. Barrett Goldstein, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave, Suite 645, Chevy Chase, MD 20815 Phone: 301-656-4545 | |
Seth Parker Worthing, PA-C Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5454 Wisconsin Ave Ste 1000, Chevy Chase, MD 20815 Phone: 301-657-1996 | |
Dr. Philip David Bobrow, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave, Suite 1660, Chevy Chase, MD 20815 Phone: 301-657-9876 Fax: 301-983-5059 |